First Observatory of Precocious and Advanced Puberty in Private Healthcare.

Status: Recruiting
Location: See all (25) locations...
Study Type: Observational
SUMMARY

The age of puberty has fluctuated throughout history. Recent data shows an increase in the age of onset of puberty signs, in the United States but also in Europe. A recent Public Health France study published in 2018 reports an increase in the incidence of precocious puberty with geographical heterogeneity. The consequences of these appearances include the early onset of menarche, short adult height and the psychological impact. Due to a lack of studies and additional data, the reasons for this development are difficult to understand. Among current hypotheses, the entanglement with the evolution of our environment is at the forefront: the action of environmental endocrine disruptors and nutritional factors could play a role in the process of early appearance of pubertal signs. The establishment of a national observatory for early and advanced puberty in collaboration with pediatric endocrinologists (on the front line) would allow a reliable and precise field approach, capable of supplementing epidemiological data, which are currently insufficient. The investigators hypothesize that the establishment of an observatory of pubertal advances (early puberty and advanced puberty) in private medicine is possible, with inclusion of at least 75% of eligible patients, and collection of at least 80% of data.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 11
Healthy Volunteers: t
View:

⁃ Precocious puberty group (PP) :

• Suspected precocious puberty (girl aged \< 8 years or boy aged \< 9 years when the first signs of development\* appear)

⁃ Advanced puberty group (AP) :

• Suspected advanced puberty (girl aged ≥ 8 and \< 10 years or boy aged ≥ 9 and \< 11 years when the first signs of development\* appear)

• First consultation with the investigator (pediatric endocrinologist).

⁃ Control group :

• Boy or girl without signs of pubertal development (Tanner 1);

• Matched to the PP group on sex and age (+/- 1 year);

• Consultation with the same investigator over the same period (same quarter) as a patient in the PP group

Locations
Other Locations
France
Pediatric practice
RECRUITING
Aix-en-provence
Hôpital Femme Mère Enfant, Hospices civils de Lyon
RECRUITING
Bron
Pediatric practice
RECRUITING
Chambray-lès-tours
Clinique du Val d'Ouest
RECRUITING
Écully
Clinique du Val d'Ouest
RECRUITING
Écully
Clinique du Val d'Ouest
RECRUITING
Écully
Pediatric practice
RECRUITING
Essey-lès-nancy
Pediatric practice
RECRUITING
Fondettes
Pediatric practice
ACTIVE_NOT_RECRUITING
Levallois-perret
Polyclinique Bordeaux rive droite
ACTIVE_NOT_RECRUITING
Lormont
Pediatric practice
RECRUITING
Lyon
Pediatric practice
ACTIVE_NOT_RECRUITING
Marseille
Pediatric practice
RECRUITING
Marseille
Pediatric practice
RECRUITING
Nice
Pediatric practice
RECRUITING
Paris
Pediatric practice
RECRUITING
Paris
Pediatric practice
ACTIVE_NOT_RECRUITING
Paris
Pediatric practice
RECRUITING
Paris
Pediatric practice
RECRUITING
Pau
Pediatric Practice
RECRUITING
Pessac
Pediatric practice
RECRUITING
Rennes
Clinique Saint jean
ACTIVE_NOT_RECRUITING
Saint-jean-de-védas
Pediatric practice
NOT_YET_RECRUITING
Saint-nazaire
Clinique rive gauche
NOT_YET_RECRUITING
Toulouse
Pediatric practice
RECRUITING
Trélazé
Contact Information
Primary
Emillie Doye, MD
emilie.doye@chu-lyon.fr
0472118890
Backup
Tiphanie GINHOUX
Tiphanie.ginhoux01@chu-lyon.fr
0427857723
Time Frame
Start Date: 2024-06-26
Estimated Completion Date: 2028-06-26
Participants
Target number of participants: 3360
Treatments
Precocious puberty group
Girl \< 8 years old or boy \< 9 years old when the first signs of development appear.
Advanced puberty group
Girl aged ≥ 8 and \< 10 years or boy ≥ 9 and \< 11 years old when the first signs of development appear.
Control group
Boy or girl without any signs of puberty development (Tanner 1)
Related Therapeutic Areas
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov